Coy Heldermon, M.D., Ph.D.
Associate Professor
Department:
MD-HEMATOLOGY/ONCOLOGY
Business Phone:
(352) 273-7832
Business Email:
coy.heldermon@medicine.ufl.edu
About Coy Heldermon
As an associate professor of medicine and breast cancer specialist in the University of Florida Division of Hematology and Oncology, my passion lies in the intersection of patient care and groundbreaking research. As an oncologist, my primary focus is on breast cancer, and I’ve dedicated my career to improving treatment options for patients. I am aware of the limitations of conventional therapies, particularly when it comes to addressing inflammatory breast cancer.
In my role, I actively engage in research aimed at developing more effective breast cancer treatments through innovative approaches. These experiments enable us to develop and refine novel treatment strategies that hold the promise of providing better outcomes for our patients. Beyond my work in breast cancer, I am also deeply committed to the field of lysosomal storage diseases. I played an instrumental role in establishing the pediatric and adult multidisciplinary lysosomal storage disease clinic at UF, which I currently direct. Here, I provide compassionate care to patients with these conditions and actively engage in clinical trials focused on gene replacement, substrate reduction and enzyme replacement therapies.
My research extends beyond the lab as well. I collaborate closely with esteemed investigators at UF to conduct studies on patient-derived xenograft tumors. These models allow us to tailor drug testing in an individualized manner, all with the ultimate goal of better serving our patients.
My interests extend even further into the realm of physician-scientist pursuits. I am deeply invested in the development of gene and stem cell therapies, with a particular emphasis on Sanfilippo syndrome Type B and other inherited disorders. In the pursuit of innovative treatments, I also possess extensive experience in utilizing viral vectors for gene therapy and harnessing the power of stem cells for gene delivery and regenerative approaches to disease treatment.
Ultimately, my dedication to patient care and advancing medical science drives every aspect of my work. It is my privilege to be a part of the medical community at UF, and I am committed to making a meaningful impact on the lives of those I serve.
Teaching Profile
Courses Taught
2019
PHA6136 Clinical Applications of Precision Medicine: Oncology
2017-2018,2021-2024,2023-2024
GMS6847 Translational Research and Therapeutics: Bench, Bedside, Community, & Policy
2018
GMS7979 Advanced Research
2018
MDC7200 Medicine Clerkship
2018
BME7980 Research for Doctoral Dissertation
2010
IDH4917 Undergrad Research
2010
IDH4905 Individual Work
2021
PHA6935 Selected Topics in Pharmacy
Board Certifications
-
Internal MedicineAmerican Board of Internal Medicine
-
OncologyAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Cancer
Areas of Interest
- Breast cancer
- Cancer – resources
- Gaucher disease
- Metachromatic leukodystrophy
- Mucopolysaccharidosis type III
- Stem cell research
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-2148-2868
Publications
2024
Association between trajectories of prescription opioid use and risk of opioid use disorder and overdose among US nonmetastatic breast cancer survivors.
Breast cancer research and treatment.
204(3):561-577
[DOI] 10.1007/s10549-023-07205-6.
[PMID] 38191684.
2024
Mucopolysaccharidosis type IIIB: a current review and exploration of the AAV therapy landscape
Neural Regeneration Research.
19(2):355-359
[DOI] 10.4103/1673-5374.377606.
[PMID] 37488890.
2023
A Pilot Study on Burnout in Medical Students (BuMS) over an Academic Year
International Medical Education.
2(3):161-174
[DOI] 10.3390/ime2030016.
2023
Central nervous system nocardiosis mimicking recurrence of diffuse large B cell lymphoma with cerebral involvement
International Journal of Infectious Diseases.
134:133-134
[DOI] 10.1016/j.ijid.2023.06.005.
2023
Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study.
Journal of managed care & specialty pharmacy.
29(2):119-127
[DOI] 10.18553/jmcp.2023.29.2.119.
[PMID] 36705287.
2023
Correction: Site-specific modifications to AAV8 capsid yields enhanced brain transduction in the neonatal MPS IIIB mouse
Gene Therapy.
30(9):736-736
[DOI] 10.1038/s41434-023-00412-2.
[PMID] 37495717.
2023
Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector
Human Molecular Genetics.
32(3):417-430
[DOI] 10.1093/hmg/ddac209.
[PMID] 35997776.
2023
Economic Burden of Sanfilippo Syndrome in the United States.
Research square.
[PMID] 37398464.
2023
Femoral Structure and Biomechanical Characteristics in Sanfilippo Syndrome Type-B Mice
International Journal of Molecular Sciences.
24(18)
[DOI] 10.3390/ijms241813988.
[PMID] 37762291.
2023
Sex differences in brain transcriptomes of juvenile Cynomolgus macaques.
Research square.
[DOI] 10.21203/rs.3.rs-3422091/v1.
[PMID] 38045237.
2023
Trends, characteristics, race, and ethnicity associated with nonadherence to antidepressants among breast cancer survivors with depression.
Journal of managed care & specialty pharmacy.
29(4):431-445
[DOI] 10.18553/jmcp.2023.29.4.431.
[PMID] 36989452.
2022
Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death.
Cancer letters.
534
[DOI] 10.1016/j.canlet.2022.215604.
[PMID] 35247515.
2022
Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population.
Journal of managed care & specialty pharmacy.
28(7):795-802
[DOI] 10.18553/jmcp.2022.28.7.795.
[PMID] 35737859.
2021
ASO Visual Abstract: A 5-Year Breast Surgeon Experience in LYMPHA at Time of ALND for Treatment of Clinical T1-4N1-3M0Â Breast Cancer
Annals of Surgical Oncology.
[DOI] 10.1245/s10434-021-10648-0.
[PMID] 34655351.
2021
Five-Year Breast Surgeon Experience in LYMPHA at Time of ALND for Treatment of Clinical T1-4N1-3M0 Breast Cancer.
Annals of surgical oncology.
28(10):5775-5787
[DOI] 10.1245/s10434-021-10551-8.
[PMID] 34365563.
2021
LC-MS lipidomics of renal biopsies for the diagnosis of Fabry disease
Journal of Mass Spectrometry and Advances in the Clinical Lab.
22:71-78
[DOI] 10.1016/j.jmsacl.2021.11.004.
[PMID] 34918004.
2021
Reflections of Healthcare Experiences of African Americans With Sickle Cell Disease or Cancer: A Qualitative Study.
Cancer nursing.
44(1):E53-E61
[DOI] 10.1097/NCC.0000000000000750.
[PMID] 31743153.
2021
Repurposing Tranexamic Acid as an Anticancer Agent.
Frontiers in pharmacology.
12
[DOI] 10.3389/fphar.2021.792600.
[PMID] 35095503.
2021
Site-specific modifications to AAV8 capsid yields enhanced brain transduction in the neonatal MPS IIIB mouse
Gene Therapy.
28(7-8):447-455
[DOI] 10.1038/s41434-020-00206-w.
[PMID] 33244179.
2021
The beta-glucuronidase intracisternal A particle insertion model results in similar overall MPSVII phenotype as the single base deletion model when on the same C57BL/6J mouse background.
Molecular genetics and metabolism reports.
27
[DOI] 10.1016/j.ymgmr.2021.100727.
[PMID] 33604242.
2021
The Value of Integrating Fluorescent Imaging and Immunohistochemistry for Future Anatomical Studies in Aesthetic Surgery: Lessons From the Cerebrospinal Fluid Circulatory System of Human Nerves and Brain.
Aesthetic surgery journal.
41(10):1197-1206
[DOI] 10.1093/asj/sjaa247.
[PMID] 32827254.
2021
Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019.
JAMA network open.
4(11)
[DOI] 10.1001/jamanetworkopen.2021.33474.
[PMID] 34812849.
2020
An Erythritol-Sweetened Beverage Induces Satiety and Suppresses Ghrelin Compared to Aspartame in Healthy Non-Obese Subjects: A Pilot Study.
Cureus.
12(11)
[DOI] 10.7759/cureus.11409.
[PMID] 33194505.
2020
Generation of Induced Pluripotent Stem Cells from a Female Patient with a Xq27.3-q28 Deletion to Establish Disease Models and Identify Therapies.
Cellular reprogramming.
22(4):179-188
[DOI] 10.1089/cell.2020.0012.
[PMID] 32608992.
2020
Multiscale Detection of Cancerous Tissue in High Resolution Slide Scans
Advances in Visual Computing.
139-153
[DOI] 10.1007/978-3-030-64559-5_11.
2020
Obesity and STING1 genotype associate with 23-valent pneumococcal vaccination efficacy.
JCI insight.
5(9)
[DOI] 10.1172/jci.insight.136141.
[PMID] 32376795.
2019
A non-catalytic function of carbonic anhydrase IX contributes to the glycolytic phenotype and pH regulation in human breast cancer cells.
The Biochemical journal.
476(10):1497-1513
[DOI] 10.1042/BCJ20190177.
[PMID] 31072911.
2019
A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers.
Oncogene.
38(22):4264-4282
[DOI] 10.1038/s41388-019-0717-6.
[PMID] 30718919.
2019
Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway.
Cell death discovery.
5
[DOI] 10.1038/s41420-019-0228-9.
[PMID] 31839995.
2019
Projected clinical benefit of surveillance imaging for early detection and treatment of breast cancer metastases.
The breast journal.
25(1):75-79
[DOI] 10.1111/tbj.13153.
[PMID] 30548515.
2018
Differential expression and function of CAIX and CAXII in breast cancer: A comparison between tumorgraft models and cells.
PloS one.
13(7)
[DOI] 10.1371/journal.pone.0199476.
[PMID] 29965974.
2018
Epidemiological, Clinical, and Histopathological Features of Breast Cancer in Haiti.
Journal of global oncology.
4:1-9
[DOI] 10.1200/JGO.17.00135.
[PMID] 30241242.
2018
UFH-001 cells: A novel triple negative, CAIX-positive, human breast cancer model system.
Cancer biology & therapy.
19(7):598-608
[DOI] 10.1080/15384047.2018.1449612.
[PMID] 29561695.
2017
Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Oncotarget.
8(17):28971-28989
[DOI] 10.18632/oncotarget.15952.
[PMID] 28423644.
2017
Periorbital and Temporal Anatomy, “Targeted Fat Grafting,” and How a Novel Circulatory System in Human Peripheral Nerves and Brain May Help Avoid Nerve Injury and Blindness During Routine Facial Augmentation.
Aesthetic surgery journal.
37(8):969-973
[DOI] 10.1093/asj/sjx089.
[PMID] 28595323.
2016
A phase I study of thymoglobulin for relapsed or refractory multiple myeloma.
Leukemia & lymphoma.
57(2):453-455
[DOI] 10.3109/10428194.2015.1049170.
[PMID] 25971909.
2016
Development of a Breast Cancer Treatment Program in Port-au-Prince, Haiti: Experiences From the Field.
Journal of global oncology.
2(1):9-14
[DOI] 10.1200/JGO.2015.000364.
[PMID] 28717677.
2016
Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells.
The Journal of clinical investigation.
126(11):4174-4186
[DOI] 10.1172/JCI86623.
[PMID] 27721239.
2016
Mucopolysaccharidosis IIIB confers enhanced neonatal intracranial transduction by AAV8 but not by 5, 9 or rh10.
Gene therapy.
23(3):263-71
[DOI] 10.1038/gt.2015.111.
[PMID] 26674264.
2016
Pigmentation of the Tongue with Lapatinib Treatment in a Patient with Advanced Breast Cancer: A Case Report.
Cancer treatment communications.
7:1-3
[PMID] 27110490.
2016
Preferred transduction with AAV8 and AAV9 via thalamic administration in the MPS IIIB model: A comparison of four rAAV serotypes.
Molecular genetics and metabolism reports.
6:48-54
[DOI] 10.1016/j.ymgmr.2015.11.006.
[PMID] 27014573.
2015
High resolution functional photoacoustic tomography of breast cancer.
Medical physics.
42(9):5321-8
[DOI] 10.1118/1.4928598.
[PMID] 26328981.
2015
Novel agents that downregulate EGFR, HER2, and HER3 in parallel.
Oncotarget.
6(12):10445-59
[PMID] 25865227.
2014
Ado-trastuzamab emtansine associated hyponatremia and intracranial hemorrhage.
Acta oncologica (Stockholm, Sweden).
53(10):1434-6
[DOI] 10.3109/0284186X.2014.920959.
[PMID] 24834794.
2014
Mucopolysaccharidosis III (Sanfilippo Syndrome)- disease presentation and experimental therapies.
Pediatric endocrinology reviews : PER.
12 Suppl 1:133-40
[PMID] 25345095.
2014
TRIM29 suppresses TWIST1 and invasive breast cancer behavior.
Cancer research.
74(17):4875-87
[DOI] 10.1158/0008-5472.CAN-13-3579.
[PMID] 24950909.
2013
Comparing Ic6 and Thalamic Aav5 Injections On Mps Iiib Model
Molecular Genetics and Metabolism.
108(2)
[DOI] 10.1016/j.ymgme.2012.11.133.
2013
Differences in Aav Serotype Dependent Distribution and Tropism Exist Within the Cns of Wild Type and Mutant Mice in the Mpsiiib Mouse Model
Molecular Therapy.
21
2013
Differences in Aav Serotype Dependent Distribution and Tropism Within the Cns of Wild Type and Mutant Mice in the Mps Iiib Mouse Model
Molecular Genetics and Metabolism.
108(2)
[DOI] 10.1016/j.ymgme.2012.11.096.
2013
Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice.
Gene therapy.
20(9):913-21
[DOI] 10.1038/gt.2013.14.
[PMID] 23535899.
2012
Effects of Minozak And/Or Genistein On the Central Nervous System of Sanfilippo Syndrome Type B Mice
Molecular Genetics and Metabolism.
105(2)
[DOI] 10.1016/j.ymgme.2011.11.060.
2010
Therapeutic Efficacy of Bone Marrow Transplant, Intracranial Aav-Mediated Gene Therapy, Or Both in the Mouse Model of Mps Iiib
Molecular Therapy.
18(5):873-880
[DOI] 10.1038/mt.2010.17.
[PMID] 20179679.
2007
Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B.
PloS one.
2(8)
[PMID] 17712420.
2001
Site-directed mutation of conserved cysteine residues does not inactivate the Streptococcus pyogenes hyaluronan synthase.
Glycobiology.
11(12):1017-24
[PMID] 11805074.
2001
Topological organization of the hyaluronan synthase from Streptococcus pyogenes.
The Journal of biological chemistry.
276(3):2037-46
[PMID] 11024012.
1999
Kinetic characterization of the recombinant hyaluronan synthases from Streptococcus pyogenes and Streptococcus equisimilis.
The Journal of biological chemistry.
274(7):4246-53
[PMID] 9933624.
1999
Properties of the hyaluronan synthase from group A Streptococcus pyogenes.
Biochemical Society transactions.
27(2):105-9
[PMID] 10093716.
1995
Expression and DNA binding of the human 52 kDa Ro/SSA autoantigen.
The Biochemical journal.
305 ( Pt 2)(Pt 2):359-62
[PMID] 7832745.
Mechanistic Elucidation of the Antitumor Properties of a Novel Death Receptor 5 Activator
.
[DOI] 10.1101/700906.
Grants
Dec 2023
ACTIVE
Effects of TLR4 antagonism on brain and bone function in MPS IIIB
Role: Principal Investigator
Funding: CURE SANFILIPPO FOU
Oct 2023
ACTIVE
The Gastrointestinal Microbiota and Breast Cancer
Role: Other
Funding: MEDICAL COLLEGE OF VIRGINIA FOUNDATION
via BRISTOL-MYERS SQUIBB FOUNDATION
Aug 2023
ACTIVE
Implementation and Evaluation of a Rare Disease Algorithm to Identify Persons at Risk of Gaucher Disease Using Data from Electronic Health Records (EHRs) in the United States
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC
via SANOFI
Aug 2023
ACTIVE
Effect of cisternal or intravenous AAVtcm8co-NAGLU on digestive function in the MPS IIIB mouse
Role: Principal Investigator
Funding: CURE SANFILIPPO FOU
Jul 2023
ACTIVE
HER1-3 and Death Receptor protein folding as therapeutic vulnerabilities
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Jun 2023
ACTIVE
Reducing racial disparity in breast cancer survival with a novel synthetic-lethal strategy
Role: Co-Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Apr 2023
ACTIVE
Novel therapeutic development for breast cancer
Role: Co-Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Apr 2023
ACTIVE
Oncogenic signaling that promotes lipid synthesis and resistance to ferroptosis
Role: Co-Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Jul 2022
ACTIVE
Novel Breast Cancer Therapeutics Targeting a Unique Subset of Disulfide Isomerases
Role: Co-Investigator
Funding: FL BREAST CANCER FOU
Apr 2022
ACTIVE
Development of first-in-class HDAC3-selective degraders for breast cancer therapy
Role: Co-Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Mar 2022
ACTIVE
A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects with Fabry Disease
Role: Principal Investigator
Funding: MEDPACE
via SANGAMO BIOSCIENCES
May 2021
ACTIVE
Novel Mechanism of Action and Translational Potential of the HDAC Inhibitor SR-4370 for Treating Breast Cancer
Role: Co-Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Jun 2020
– Nov 2023
Novel immunologic therapy of soft tissue sarcoma
Role: Principal Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Jun 2020
– Nov 2023
Molecular mechanisms and pharmacologic targeting of lipogenesis in breast cancer
Role: Other
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Jun 2020
– May 2023
Lipidnanoparticle vaccines targeting metastatic lung cancer from osteosarcoma
Role: Co-Project Director/Principal Investigator
Funding: FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE
May 2020
– Jun 2021
Task Order #7 – AAV-mediated therapy for MPS IIIB
Role: Principal Investigator
Funding: *LACERTA THERAPEUTICS
Jul 2019
– Jun 2021
Novel oral targeted breast carcinoma vaccine
Role: Co-Investigator
Funding: FL BREAST CANCER FOU
May 2019
ACTIVE
A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease.
Role: Principal Investigator
Funding: IDORSIA PHARMACEUTICAL LTD
Aug 2018
– Aug 2023
A Multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease
Role: Principal Investigator
Funding: IDORSIA PHARMACEUTICAL LTD
Jul 2018
– Dec 2020
A new approach for eradicating metastatic, drug-resistant breast cancers
Role: Co-Investigator
Funding: OCALA ROYAL DAMES FOR CANCER RESEARCH
Feb 2018
– Jan 2019
Novel isoform-selective HDAC inhibitor for enhancing cancer immunotherapy against breast cancer
Role: Co-Investigator
Funding: FL BREAST CANCER FOU
Nov 2017
– Feb 2022
A Phase I, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects with Mucopolysaccharidosis I (MPS I)
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC
via SANGAMO BIOSCIENCES
Sep 2017
– Jun 2021
UFHCC Triple Negative Breast Cancer (TNBC) Pilot Project Program
Role: Project Manager
Funding: MULTIPLE SPONSORS
Aug 2017
– Nov 2023
Optimizing AAV Vectors for Central Nervous System transduction
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
May 2017
– Jun 2018
Gene therapy with intracranial delivery of capsid enhanced AAV NAGLU
Role: Principal Investigator
Funding: FUNDACJA SANFILIPPO
Mar 2017
– Sep 2022
Neural and mesenchymal stem cell mediated gene therapy for Sanfilippo Syndrome B
Role: Principal Investigator
Funding: THE SANFILIPPO CHILDRENS RES FOU
Mar 2017
– Mar 2019
Neural and mesenchymal stem cell mediated gene therapy for Sanfilippo Syndrome B
Role: Principal Investigator
Funding: CURE SANFILIPPO FOU
Dec 2016
– Sep 2022
A Phase 2b/3 Prospective, Randomized, Double-Blind, Sham-Controlled Trial
of VTS-270 (2-hydroxypropyl-?-cyclodextrin) in Subjects with Neurologic
Manifestations of Niemann-Pick Type C1 (NPC1) Disease
Role: Principal Investigator
Funding: CTI CLINICAL TRIAL SERVICES
May 2016
– Jun 2019
Gene therapy with intracranial delivery of capsid enhanced AAV NAGLU
Role: Principal Investigator
Funding: SAN FILIPPO CHILDRENS FOU
May 2016
– Jun 2018
Gene therapy with intracranial delivery of capsid enhanced AAV NAGLU
Role: Principal Investigator
Funding: SANFILIPPO INITIATIVE E V
Mar 2016
– Jun 2021
Early markers of subclinical pulmonary vascular radiation toxicity in breast cancer
Role: Co-Investigator
Funding: FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE
Mar 2016
– Aug 2019
PHARMACOLOGIC INHIBITION OF ACETYLTRANSFERASE CBP/P300 AS ANEW THERAPEUTIC APPROACH FOR BREAST CANCER
Role: Project Manager
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Dec 2015
– Nov 2021
Miscellaneous Donors
Role: Principal Investigator
Funding: MISCELLANEOUS DONORS
Jun 2015
– Sep 2019
Novel agents that simultaneously downregulate Her2, EGFR, and Her3
Role: Project Manager
Funding: US ARMY MED RES ACQUISITION
Apr 2015
– Jun 2021
Clinical and Translational Science Institute (CTSI)
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Feb 2015
– Oct 2023
UF Health Cancer Center Pilot Project Grants funded through the Florida Consortium of National Cancer Institute Centers Program
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Feb 2015
– Jan 2017
Patient derived xenograft model studies of metastases in triple negative breast cancer
Role: Principal Investigator
Funding: UF FOUNDATION
Jul 2014
– Dec 2018
The Role of the Intestinal Microbiota in the Development of Anxiety and Depression in Breast Cancer Patients Receiving Chemotherapy.
Role: Project Manager
Funding: FL BREAST CANCER FOU
Jun 2014
– May 2016
Endobronchial Photoacoustic Microscopy for Staging of Lung Cancer
Role: Project Manager
Funding: US ARMY MED RES ACQUISITION
Apr 2013
– Mar 2019
Carbonic anhydrase and pH control in breast cancer cells
Role: Project Manager
Funding: NATL INST OF HLTH NCI
Mar 2010
– Feb 2016
Transplacental stem cell transplantation and evaluation of therapeutic effect
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDDK
Jul 2007
– May 2022
Breast Cancer Research
Role: Project Manager
Funding: UF FOUNDATION
Apr 2002
– Jul 2017
02032110
Role: Principal Investigator
Funding: NATL CANCER INST OF CANADA
Education
Fellowship – Oncology
2008
·
Barnes-Jewish Hospital
Residency – Internal Medicine
2004
·
Barnes – Jewish Hospital
Internship – Obstetrics and Gynecology
2002
·
Stanford Hospital
Medical Degree
2002
·
University of Oklahoma
Contact Details
Phones:
- Business:
- (352) 273-7832
Emails:
- Business:
- coy.heldermon@medicine.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100278
GAINESVILLE FL 32610 - Business Street:
-
1535 GALE LEMERAND DR
GAINESVILLE FL 32610